Your browser doesn't support javascript.
loading
Development and use of health outcome descriptors: a guideline development case study.
Baldeh, Tejan; Saz-Parkinson, Zuleika; Muti, Paola; Santesso, Nancy; Morgano, Gian Paolo; Wiercioch, Wojtek; Nieuwlaat, Robby; Gräwingholt, Axel; Broeders, Mireille; Duffy, Stephen; Hofvind, Solveig; Nystrom, Lennarth; Ioannidou-Mouzaka, Lydia; Warman, Sue; McGarrigle, Helen; Knox, Susan; Fitzpatrick, Patricia; Rossi, Paolo Giorgi; Quinn, Cecily; Borisch, Bettina; Lebeau, Annette; de Wolf, Chris; Langendam, Miranda; Piggott, Thomas; Giordano, Livia; van Landsveld-Verhoeven, Cary; Bernier, Jacques; Rabe, Peter; Schünemann, Holger J.
Afiliação
  • Baldeh T; Department of Health Research Methodology, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main Street West, Hamilton, ON, L8N 4K1, Canada.
  • Saz-Parkinson Z; Michael G. DeGroote Cochrane Canada and MacGRADE Centres, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
  • Muti P; European Commission, Joint Research Centre (JRC), Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy.
  • Santesso N; Department of Health Research Methodology, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main Street West, Hamilton, ON, L8N 4K1, Canada.
  • Morgano GP; Department of Oncology, McMaster University, Hamilton, Canada.
  • Wiercioch W; Department of Health Research Methodology, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main Street West, Hamilton, ON, L8N 4K1, Canada.
  • Nieuwlaat R; Michael G. DeGroote Cochrane Canada and MacGRADE Centres, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
  • Gräwingholt A; Cochrane GRADEing Methods Group, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
  • Broeders M; Department of Health Research Methodology, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main Street West, Hamilton, ON, L8N 4K1, Canada.
  • Duffy S; Michael G. DeGroote Cochrane Canada and MacGRADE Centres, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
  • Hofvind S; Department of Health Research Methodology, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main Street West, Hamilton, ON, L8N 4K1, Canada.
  • Nystrom L; Michael G. DeGroote Cochrane Canada and MacGRADE Centres, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
  • Ioannidou-Mouzaka L; Department of Health Research Methodology, Evidence and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, 1280 Main Street West, Hamilton, ON, L8N 4K1, Canada.
  • Warman S; Michael G. DeGroote Cochrane Canada and MacGRADE Centres, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.
  • McGarrigle H; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
  • Knox S; Private Group Practice for Radiology, Radiologie am Theater, Paderborn, Germany.
  • Fitzpatrick P; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
  • Rossi PG; Department for Health Evidence, Radboud University Medical Center, PO Box 9101, 6525 EZ, HB, Nijmegen, The Netherlands.
  • Quinn C; Dutch Expert Centre for Screening, PO Box 6873, 6503, GJ, Nijmegen, the Netherlands.
  • Borisch B; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
  • Lebeau A; Centre for Cancer Prevention, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, United Kingdom.
  • de Wolf C; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
  • Langendam M; Cancer Registry of Norway, PO 5313, Majorstua, 0304, Oslo, Norway.
  • Piggott T; Oslo Metropolitan University, Pilestredet 48, 0167, Oslo, Norway.
  • Giordano L; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
  • van Landsveld-Verhoeven C; Umeå University, 90187, Umeå, Sweden.
  • Bernier J; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
  • Rabe P; Leto Gynecological-Surgical and Obstetrical Clinic, 18, Avenue Kifissias, 11526, Athens, Greece.
  • Schünemann HJ; European Commission Initiative on Breast Cancer Guidelines Development Group, European Commission, JRC, Ispra, Italy.
Health Qual Life Outcomes ; 18(1): 167, 2020 Jun 05.
Article em En | MEDLINE | ID: mdl-32503619
BACKGROUND: During healthcare guideline development, panel members often have implicit, different definitions of health outcomes that can lead to misunderstandings about how important these outcomes are and how to balance benefits and harms. McMaster GRADE Centre researchers developed 'health outcome descriptors' for standardizing descriptions of health outcomes and overcoming these problems to support the European Commission Initiative on Breast Cancer (ECIBC) Guideline Development Group (GDG). We aimed to determine which aspects of the development, content, and use of health outcome descriptors were valuable to guideline developers. METHODS: We developed 24 health outcome descriptors related to breast cancer screening and diagnosis for the European Commission Breast Guideline Development Group (GDG). Eighteen GDG members provided feedback in written format or in interviews. We then evaluated the process and conducted two health utility rating surveys. RESULTS: Feedback from GDG members revealed that health outcome descriptors are probably useful for developing recommendations and improving transparency of guideline methods. Time commitment, methodology training, and need for multidisciplinary expertise throughout development were considered important determinants of the process. Comparison of the two health utility surveys showed a decrease in standard deviation in the second survey across 21 (88%) of the outcomes. CONCLUSIONS: Health outcome descriptors are feasible and should be developed prior to the outcome prioritization step in the guideline development process. Guideline developers should involve a subgroup of multidisciplinary experts in all stages of development and ensure all guideline panel members are trained in guideline methodology that includes understanding the importance of defining and understanding the outcomes of interest.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Avaliação de Resultados em Cuidados de Saúde / Guias de Prática Clínica como Assunto / Medicina Baseada em Evidências Tipo de estudo: Etiology_studies / Guideline / Qualitative_research / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Avaliação de Resultados em Cuidados de Saúde / Guias de Prática Clínica como Assunto / Medicina Baseada em Evidências Tipo de estudo: Etiology_studies / Guideline / Qualitative_research / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article